Compare Altria Group Inc (MO) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Philip Morris International Inc. — how do they compare? Altria Group Inc trades at $71.31 (market cap $115.85B), while Philip Morris International Inc. trades at $200.2 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 2.6× Altria Group Inc's market cap, and Altria Group Inc pays the higher dividend (6.4%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Philip Morris International Inc. for 85 Days on average.
| MO | PM | |
|---|---|---|
Market Cap | $115.85B | $300.33B |
Volume | 6,934,962 | 3,935,700 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $74.92 | $200.50 |
52-Week Low | $54.72 | $144.33 |
Typical Hold Time | 154 Days | 85 Days |
Enterprise Value | $138.06B | $343.44B |
Dividend Yield | 6.4% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.43, up 4.2% today, showing strong momentum despite mixed earnings history with two misses and one beat in recent quarters. The stock maintains a 6.6% dividend yield with 60 consecutive annual increases, supported by robust cash flow generation. Technical indicators show a bullish trend with current price near resistance at $71, while fundamentals reveal stable revenue around $20B annually but declining profit margins from 55.1% in 2024 to 34.5% in 2025.
MO presents a high-yield opportunity with strong cash flows but faces significant headwinds including negative shareholder equity, regulatory pressures, and declining cigarette volumes. Analyst consensus remains positive with 62% buy ratings and $69.71 price target, though the stock trades slightly above this target. The company's transition to smoke-free products remains critical for long-term sustainability amid changing consumer preferences.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
